Browse the evidence

Both semaglutide and tirzepatide show gastrointestinal side effects including nausea, vomiting, pancreatitis, and diarrhea.

Clinicians should be aware of these common gastrointestinal side effects when prescribing these medications.

Tirzepatide is preferred over semaglutide due to less reported side effects and enhanced benefits in promoting bone formation.

Tirzepatide may be a better option for patients needing obesity management with fewer side effects.

GLP-1 receptor agonists reduced systolic blood pressure (SBP) by 3.4 mmHg and diastolic blood pressure (DBP) by 0.9 mmHg.

GLP-1 receptor agonists can be considered for managing blood pressure in overweight or obese patients.

Incretin-based therapy did not increase the risk of hypoglycaemia or pancreatitis.

Clinicians can consider incretin-based therapies as safe options for managing obesity and hypertension without increasing hypoglycaemia or pancreatitis risk.

Rational protein engineering and delivery innovations transformed incretin biology into global metabolic therapeutics.

Innovations in protein engineering can enhance therapeutic efficacy.

The balance between adipose tissue reduction and lean mass preservation with GLP-1RAs remains incompletely understood in clinical settings.

Further research is needed to clarify the effects of GLP-1RAs on body composition in clinical practice.

Obesity is associated with increased risk of cancer, accounting for approximately 10% of new cancer diagnoses annually in the US.

Healthcare practitioners should consider obesity as a significant risk factor for cancer in their patients.

Endogenous natural peptides have attracted increasing attention for fighting obesity.

Practitioners should consider the potential of endogenous peptides in obesity management.

Incretin-based therapies, including GLP-1 and GIP, enhance insulin secretion from pancreatic beta cells.

Practitioners can consider incretin-based therapies as a viable option for enhancing insulin secretion in diabetes management.

Adverse events from semaglutide were generally mild to moderate gastrointestinal effects and occurred more frequently in the semaglutide group.

Clinicians should monitor for mild to moderate gastrointestinal side effects in patients treated with semaglutide.

Semaglutide reduced frailty burden after 52 weeks of treatment.

Semaglutide may be beneficial in reducing frailty in patients with obesity-related HFpEF over a year.

Semaglutide (SEM) and tirzepatide (TIR) use was associated with greater annualized total hip (TH) bone loss in patients without diabetes mellitus (DM) compared to controls.

Practitioners should monitor bone health in patients using GLP-1 RAs, especially those without DM.

Total hip (TH) bone loss was comparable between GLP-1 RA users and controls among patients with diabetes mellitus (DM).

Bone health monitoring may be less critical for patients with DM using GLP-1 RAs.

HEC-C070, with moderate GCG agonism, significantly affects weight loss and liver function in obese mice.

HEC-C070 may be a viable option for addressing obesity and liver function issues.

Long-term cardiovascular outcome data for recent anti-obesity medications remain inconclusive or lacking.

Practitioners should be cautious and consider the lack of long-term data when prescribing these medications.

Semaglutide users had higher rates of pneumonia (2.97 % vs 0.85 %, p < 0.05) compared to non-users.

Clinicians should be aware of the increased risk of pneumonia in patients using semaglutide.

Patients with longer semaglutide use had a higher incidence of urinary tract infection (4.03 % vs 1.27 %, p < 0.05) and acute kidney injury (3.18 % vs 0.85 %, p < 0.05).

Healthcare providers should monitor for urinary tract infections and kidney injury in patients on long-term semaglutide.

The need for additional lumbar fusion was associated with both semaglutide use (17.0 % vs. 6.4 %, p < 0.0001) and duration (28.3 % vs. 4.8 %, p < 0.0001).

Surgeons should consider the potential for increased surgical interventions in patients using semaglutide.

Genetic variation within the leptin-melanocortin pathway may predict response to endoscopic interventions and guide personalized treatment selection.

Understanding genetic factors can help tailor obesity treatments to individual patients.

Sitagliptin elicited modest glycemic improvements without substantial alterations in lipid composition.

Sitagliptin may be less effective than semaglutide for lipid management in T2DM patients.

Atherogenic dyslipidemias are a major contributor to ASCVD within the CKM framework.

Recognize and address dyslipidemias in patients with obesity to mitigate cardiovascular disease risk.

Moorehead-Ardelt scores were higher in the bypass group at 2 years but showed no statistically significant differences later on.

Practitioners should note that while bypass may improve certain quality of life metrics initially, this effect may not persist long-term.

Erectile dysfunction (ED) affects up to three out of four individuals with diabetes.

Healthcare providers should be aware of the high prevalence of ED in diabetic patients.

Preliminary reports have raised concerns about a possible association between GLP-1 RA use and erectile dysfunction.

Clinicians should monitor erectile function in patients using GLP-1 RAs.